Lung cancer immune study aims to unlock biomarkers for better treatment

NCT ID NCT04432142

Ongoing Knowledge-focused Sponsor: Maastricht Radiation Oncology Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how the immune system changes in 45 people with stage III non-small cell lung cancer who receive chemoradiation followed by the drug durvalumab. Researchers want to find immune markers that could predict how well the treatment works. The goal is to improve future therapies by understanding these immune effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab
What this could lead to: If successful, this study could identify immune biomarkers that help predict which patients benefit most from durvalumab after chemoradiation, improving personalized treatment.
What could go wrong: This is a small, early-phase observational study (45 participants) focused on immune profiling, not on proving treatment effectiveness. Results may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Maastricht Radiation Oncology (MAASTRO clinic)

Maastricht, 6229 ET, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.